BioLineRx (NASDAQ:BLRX) – Oppenheimer increased their Q2 2018 earnings estimates for shares of BioLineRx in a report released on Tuesday, May 22nd. Oppenheimer analyst M. Breidenbach now anticipates that the biotechnology company will post earnings of ($0.06) per share for the quarter, up from their previous estimate of ($0.07). Oppenheimer also issued estimates for BioLineRx’s Q3 2018 earnings at ($0.06) EPS, Q4 2018 earnings at ($0.06) EPS, FY2018 earnings at ($0.25) EPS, FY2019 earnings at ($0.26) EPS and FY2020 earnings at ($0.19) EPS.
BLRX has been the topic of several other reports. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of BioLineRx in a research note on Tuesday, March 6th. Zacks Investment Research raised BioLineRx from a “sell” rating to a “hold” rating in a research note on Tuesday, February 20th. Finally, ValuEngine raised BioLineRx from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. BioLineRx presently has a consensus rating of “Buy” and a consensus target price of $2.80.
BioLineRx (NASDAQ:BLRX) last issued its quarterly earnings results on Tuesday, May 22nd. The biotechnology company reported ($0.06) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.07) by $0.01.
An institutional investor recently raised its position in BioLineRx stock. Renaissance Technologies LLC increased its position in BioLineRx (NASDAQ:BLRX) by 60.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 434,700 shares of the biotechnology company’s stock after purchasing an additional 164,500 shares during the period. Renaissance Technologies LLC owned 0.41% of BioLineRx worth $474,000 at the end of the most recent reporting period. 35.72% of the stock is currently owned by hedge funds and other institutional investors.
BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.